GB HealthWatch, a San Diego, CA-based genetic-based preventive health company, raised $3.5m in pre-series C funding.
The investors participating in the round are Trinity Power LLC, a series B investor, and the founder of GB HealthWatch.
The company plans to use the funds to grow its national leadership position in advanced genetic testing and developing precision medicine applications for the prevention and treatment of dyslipidemia, coronary heart disease, type 2 diabetes, and Alzheimer’s disease, and build the infrastructure of their preventive health ecosystem.
Led by Dr. Li Shen, President, and Dr. Mendel Roth, Lead Scientist of Genetics and Molecular Biology, GB HealthWatch is a genetic-based preventive health company, which develops technologies to facilitate research on the molecular mechanisms, clinical efficacy, and cost-effectiveness of translating genetic insights into personalized prevention and treatment strategies for complex diseases. GB HealthWatch offers the following products and services:
- GBinsight Genetic Testing and Analysis
- HealthWatch 360 mobile app and online tool
- HealthWatch 360 Research Portal for academics, clinicians and research institutes to study diet and health interactions.
With this round of pre-series C funding and subsequent series C funding, the company will further develop and refine a platform that will enable physicians to prescribe genomics-guided, precision therapeutics that will maximize clinical efficacy, limit healthcare costs, and empower patients and their at-risk family members to engage in preventive care.